Foren & Soziale Netzwerke zur BOSTON SCIENTIFIC Aktie

 

Kursziel: 49.0105 €

1. Volume hitting last 2 quarters, starting to create is own living volume shelf. 2. Sitting on its 61% fib 3. I dont mind a death cat bounce to $75 if this is to remain bearish, but if bullish - very powerful wave 3.

Good Afternoon, Hope all is well. Here is my TA on Boston Scientific. What I'm Seeing Looking at Boston Scientific on the weekly chart, the dominant trend is still bearish. Price has fallen from roughly $105–$110 to $44, remains below a declining weekly trend/average, and has yet to establish a convincing sequence of higher highs and higher lows. But the behavior of the decline is changing. I've marked three significant selling events. Earlier in the decline, heavy volume produced substantial downside movement. More recently, additional selling has produced progressively less downside, while volume itself has begun to contract. At the same time, my daily momentum has turned positive for the first time since November 2025, and the weekly negative directional component has weakened relative to the broader trend-strength measure. To me, this potentially represents: aggressive markdown → diminishing selling pressure → stabilization → potential accumulation. The bottom isn't confirmed, but I think the $

I will be buying this box for a long term hold. This level is huge and I really like how we have tested many levels on the way down that we can easily push through to all time highs in the future if we ever pump again.

? Boston Scientific (BSX): A Strategic Play at Major Support? ? ?️ Technical Setup ? Trading near $49, BSX has pulled back significantly from its $110 highs to hover near its 52-week low. ? The RSI indicates deeply oversold conditions as the price tests a critical historical support zone between $47 and $48. ?? Buying at these established support levels offers an exceptionally strong risk-to-reward ratio for a potential entry. ⚖️✨ ? Fundamental Drivers ? The recent sell-off was triggered by lowered 2026 revenue guidance (6.5%–8.0%) due to Watchman product slowdowns and sector competition. ⚠️? Despite these challenges, Q1 2026 revenue remained robust at $5.2 billion. ?? Furthermore, the pending $14.5 billion acquisition of Penumbra serves as a massive catalyst for future growth. ?? Analysts maintain a "Buy" consensus with average price targets around $80, suggesting over a 60% potential upside. ?? ⚖️ The Verdict ? Accumulating shares in this $47–$48 oversold support zone is a smart strategy for tradi

https://de.marketscreener.com/boerse-nachrichten/boston-scientific-uebertrifft-erstquartalszahlen-senkt-jedoch-jahresprognose-ce7f59d8d189fe22https://de.marketscreener.com/boerse-nachrichten/boston-scientific-corporation-vermeldet-positive-ergebnisse-der-zulassungsrelevanten-fracture-ide-st-ce7f5ad9db8eff21Boston Scientific Corporation vermeldet positive Ergebnisse der zulassungsrelevanten FRACTURE-IDE-Studie zum Seismiq 4CE Koronar-Lithotripsie-... -Tamakoschy

Kursziel: 85.48 €

Kursziel: 82.0608 €

Kursziel: 85.15 €

Kursziel: 85.15 €

Kursziel: 76.392 €

Kursziel: 77.004 €

Kursziel: 75.4551 €

Kursziel: 99.8545 €

Kursziel: 84.2251 €

Kursziel: 76.4104 €

Kursziel: 80.5938 €

Kursziel: 77.814 €

Kursziel: 79.7548 €

Kursziel: 91.329 €